Chronic Kidney Disease (CKD) is the most common disease of geriatric cats and affects approximately 30-40% of cats older than 15 years. It is characterized by progressive and irreversible loss of renal function. Early diagnosis and appropriate nutritional management can significantly slow disease progression and improve quality of life. Correct classification with the IRIS (International Renal Interest Society) staging system forms the basis of treatment planning. This article reviews the pathophysiology of feline CKD, early diagnostic tools, IRIS staging, and strategies for nutrition and quality-of-life management.
Signs That Require Veterinary Evaluation
- Excessive drinking (polydipsia) and excessive urination (polyuria), often the earliest signs
- Weight loss, especially loss of muscle mass (cachexia)
- Reduced appetite or selective eating lasting longer than 48 hours
- Vomiting, especially in the morning or with bile
- Halitosis with a uremic, ammonia-like odor
- Lethargy and weakness that gradually worsen
- Signs of dehydration, such as reduced skin elasticity or dry mucous membranes
1. What Is CKD? Pathophysiology
The kidneys perform critical functions including filtration, waste removal, electrolyte balance, blood pressure regulation, and erythropoietin production. In CKD, nephrons, the functional units of the kidney, are progressively lost. Overt clinical signs usually do not appear until 65-75% of renal function has been lost, which is why early detection is so important.
With chronic injury, functioning nephrons are replaced by fibrosis. Remaining nephrons undergo compensatory hypertrophy, but this hyperfiltration causes additional long-term damage and perpetuates a vicious cycle.
As filtration declines, BUN, creatinine, phosphorus, and uremic toxins such as indoxyl sulfate accumulate in the blood. These contribute to nausea, anorexia, oral ulceration, and anemia.
The kidneys lose the ability to concentrate urine, leading to polyuria, fluid loss, and compensatory polydipsia. Urine specific gravity drops (USG <1.035). In later stages, chronic dehydration becomes common.
2. Causes
| Cause | Description | Clinical Note |
|---|---|---|
| Idiopathic | Most cases; no specific cause can be identified | Age-related nephron degeneration is often presumed |
| Tubulointerstitial nephritis | The most common histopathologic finding | Chronic inflammation with fibrosis |
| Polycystic kidney disease (PKD) | Autosomal dominant in Persian and related breeds | Genetic testing is available; ultrasonography helps confirm diagnosis |
| Lymphoma | Renal lymphoma, especially in FeLV-positive cats | Often associated with bilateral renal enlargement |
| Amyloidosis | Breed predisposition in Abyssinian and Siamese cats | Associated with amyloid deposition |
| Post-acute kidney injury | After lily intoxication, NSAID exposure, or ethylene glycol toxicity | AKI may progress to CKD |
| Pyelonephritis | Chronic renal infection | Urine culture helps establish the diagnosis |
| Hypertension | May be both a cause and a consequence of CKD | Retinal damage can lead to blindness |
Lily Toxicity Is Fatal in Cats
Lilium and Hemerocallis species can cause acute kidney failure in cats. Any part of the plant, including leaves, flowers, pollen, or vase water, is toxic. Without treatment within 72 hours, exposure can be fatal. These plants should never be kept in homes with cats.
3. Early Diagnosis: SDMA and Other Biomarkers
| Biomarker | Value for Early Diagnosis | Clinical Meaning |
|---|---|---|
| SDMA (Symmetric Dimethylarginine) | ⭐⭐⭐ Earliest | Increases when approximately 25% of renal function is lost; independent of muscle mass; rises about 17 months earlier than creatinine on average |
| Creatinine | ⭐⭐ Later | Typically rises after 75% renal function loss; affected by muscle mass and can be falsely low in thin cats |
| BUN | ⭐ Latest | Affected by diet, especially high protein intake, dehydration, and gastrointestinal bleeding |
| Urine specific gravity (USG) | ⭐⭐ Early clue | USG <1.035 in cats suggests reduced concentrating ability, but is not diagnostic on its own |
| UPC (Urine Protein:Creatinine Ratio) | Assessment of proteinuria | UPC >0.4 in cats indicates clinically relevant proteinuria and possible glomerular injury |
| Blood pressure | Hypertension screening | Systolic pressure >160 mmHg indicates hypertension and increases the risk of retinal injury |
SDMA: A Major Advance in Early Detection
SDMA has changed the landscape of early CKD diagnosis. It can increase months to years before creatinine rises. Annual screening with SDMA, especially in cats older than 7 years, is widely recommended. IRIS has also incorporated SDMA into staging criteria (IRIS 2023). Because it is less influenced by muscle mass, it is particularly useful in thin and geriatric cats.
4. The IRIS Staging System
The IRIS (International Renal Interest Society) staging system is used to define CKD severity and guide treatment planning.
| IRIS Stage | Creatinine (µmol/L) | Creatinine (mg/dL) | SDMA (µg/dL) | Clinical Interpretation |
|---|---|---|---|---|
| Stage 1 | <140 | <1.6 | <18 | Subclinical disease; diagnosed through poor urine concentration, proteinuria, or imaging changes |
| Stage 2 | 140-250 | 1.6-2.8 | 18-25 | Mild azotemia; mild polyuria/polydipsia; clinical signs may still be subtle |
| Stage 3 | 251-440 | 2.9-5.0 | 26-38 | Moderate azotemia; anorexia, vomiting, weight loss, and dehydration become common |
| Stage 4 | >440 | >5.0 | >38 | Severe azotemia with risk of uremic crisis, anemia, metabolic acidosis, and death |
4.1 Substaging: Proteinuria and Hypertension
- Non-proteinuric: UPC <0.2
- Borderline: UPC 0.2-0.4
- Proteinuric: UPC >0.4
- Proteinuria accelerates progression and requires intervention
- Normal: <140 mmHg
- Prehypertensive: 140-159 mmHg
- Hypertensive: 160-179 mmHg
- Severe hypertension: ≥180 mmHg
- Retinal detachment may lead to sudden blindness
5. Complications of CKD
| Complication | Mechanism | Management |
|---|---|---|
| Hyperphosphatemia | Reduced phosphorus excretion and disturbed calcium-phosphorus balance | Renal diet with low phosphorus plus phosphate binders such as aluminum hydroxide when needed |
| Metabolic acidosis | Impaired acid excretion and reduced bicarbonate buffering | Alkalinizing diet and potassium citrate supplementation when indicated |
| Non-regenerative anemia | Reduced erythropoietin production | Darbepoetin together with iron support when appropriate |
| Hypertension | RAAS activation and sodium retention | Amlodipine; benazepril or telmisartan as indicated |
| Hypokalemia | Potassium loss due to polyuria | Potassium gluconate or citrate supplementation and potassium-supportive nutrition |
| Chronic dehydration | Loss of urine-concentrating ability | Subcutaneous fluids at home when indicated; wet food |
| Uremic gastritis / stomatitis | Uremic toxins and mucosal irritation | Antiemetics such as maropitant, H2 blockers or PPIs, and oral care |
| Secondary hyperparathyroidism | Hyperphosphatemia causes rising PTH and bone resorption | Phosphorus control; calcitriol only with careful case selection |
6. Nutritional Management: The VetKriter Approach
VetKriter Nutrition Principle
Nutrition is the cornerstone of therapy in feline CKD. Renal diets are among the few interventions shown to slow CKD progression and extend survival two- to threefold in cats (Elliott et al., 2000; Ross et al., 2006). Phosphorus restriction, protein optimization, and increased water intake are the three central strategies.
6.1 Core Principles of the Renal Diet
| Parameter | Standard Diet | Renal Diet | Why It Matters |
|---|---|---|---|
| Phosphorus | 1.0-1.5% DM | 0.3-0.6% DM | Helps control hyperphosphatemia and reduce secondary hyperparathyroidism |
| Protein | 30-40% DM | 26-32% DM | Helps reduce nitrogenous waste, but excessive restriction causes muscle loss; balance is essential |
| Sodium | 0.3-0.5% | 0.15-0.3% | Supports blood pressure control and reduces renal workload |
| Potassium | 0.6% | 0.7-1.0% (increased) | Helps compensate for hypokalemia |
| Omega-3 (EPA/DHA) | Low | High | May reduce glomerular inflammation and exert anti-fibrotic effects |
| B vitamins | Normal | Increased | Compensates for urinary B-vitamin losses caused by polyuria |
| Antioxidants | Normal | Increased | Helps reduce oxidative stress with vitamin E, vitamin C, and carotenoids |
| Caloric density | Normal | High | Allows adequate energy intake with smaller food volume, important in anorectic cats |
The Protein Paradox: Neither Too Little nor Too Much
Protein restriction in CKD remains a nuanced issue. Excessive restriction leads to muscle loss, sarcopenia, and declining body condition, all of which worsen prognosis. Cats are obligate carnivores and require more protein than dogs. The goal is adequate amounts of high-quality protein while keeping phosphorus as low as possible. Good renal diets solve this by using high-quality, low-phosphorus protein sources.
6.2 Nutrition by IRIS Stage
| IRIS Stage | Serum Phosphorus Target | Nutritional Approach |
|---|---|---|
| Stage 1 | <4.5 mg/dL | High-quality maintenance nutrition, increased water intake, encouragement of wet food, and phosphorus monitoring |
| Stage 2 | <4.5 mg/dL | Transition to a renal diet, ideally over 7-14 days; phosphate binders may be needed in some cases |
| Stage 3 | <5.0 mg/dL | Renal diet plus phosphate binder, appetite support, wet food, and antiemetic therapy as needed |
| Stage 4 | <6.0 mg/dL | Renal diet if tolerated, palliative support, and feeding-tube discussion in selected cases |
6.3 Strategies for Transitioning to a Renal Diet
Gradual Transition Protocol
Many cats with CKD do not accept a renal diet immediately. A patient and gradual transition is critical.
Days 1-3
75% previous food
25% renal diet
Days 4-7
50% previous food
50% renal diet
Days 8-10
25% previous food
75% renal diet
Days 11-14
100% renal diet
Practical tips: Warm the food, try different flavors or brands, and offer food by hand when needed. If the cat absolutely refuses the renal diet, not eating is worse than eating a non-renal but acceptable food. Any nutritionally adequate intake is better than starvation (Roudebush et al., 2009).
6.4 Phosphate Binders
| Phosphate Binder | How It Is Used | Key Note |
|---|---|---|
| Aluminum hydroxide | Mixed with food and given with meals | Most widely used and effective; long-term monitoring for aluminum accumulation is advisable |
| Calcium carbonate | Given with meals | Can contribute to hypercalcemia; use cautiously in cats with calcium oxalate history |
| Lanthanum carbonate | Given with meals | Contains no calcium and is often well tolerated in cats |
| Chitosan-based binders | Sprinkled onto food | Palatable formulations can improve adherence |
7. Water Intake and Hydration Strategies
- Wet food: 70-80% moisture and the most effective form of oral hydration
- Water fountain: Flowing water often encourages drinking
- Add water to dry food: Soak kibble with warm water
- Multiple water stations: Place bowls in different parts of the home
- Flavoring the water: A small amount of tuna water or unsalted chicken broth may help
- In moderate to advanced CKD, subcutaneous fluids at home may be recommended by the veterinarian
- Fluid type: Lactated Ringer's solution or 0.9% NaCl
- Volume: Commonly 75-150 mL/day, depending on veterinary instruction
- Administration: Usually into the interscapular region with a butterfly needle
- Can significantly improve quality of life
8. Medical Therapy
| Medication | Indication | Clinical Note |
|---|---|---|
| Benazepril / Telmisartan | Adjunctive therapy for proteinuria and hypertension | RAAS inhibition reduces glomerular pressure; telmisartan is licensed for cats in many regions |
| Amlodipine | First-line therapy for hypertension | Calcium-channel blocker; usual goal is systolic blood pressure <160 mmHg |
| Maropitant (Cerenia) | Uremic nausea and vomiting | NK1 receptor antagonist; may improve appetite indirectly |
| Mirtazapine | Appetite stimulation | Transdermal formulation is available; dose adjustment may be needed in CKD cats |
| Darbepoetin | Non-regenerative anemia (HCT <20%) | Erythropoietin analogue, usually paired with iron supplementation |
| Potassium gluconate / citrate | Hypokalemia | Helps prevent muscle weakness and hypokalemic polymyopathy |
| Phosphate binders | Hyperphosphatemia when diet alone is insufficient | Must be given with meals; product choice depends on the patient |
9. Monitoring Quality of Life
Home Monitoring Guide
- Appetite: Track daily food intake and report any decline
- Water intake: Watch for either an increase or a decrease
- Body weight: Weigh weekly and monitor BCS; the practical goal is usually 4-5/9
- Urination: Observe frequency, volume, and color; clumping litter makes this easier
- Activity: Monitor energy level, desire to play, and social interaction
- Vomiting: Track both frequency and character
- Laboratory monitoring: Blood and urine checks every 1-3 months depending on veterinary recommendation
Assessing Quality of Life
CKD is a chronic, progressive disease. The aim of treatment is not cure, but preservation of quality of life and slowing of decline. Caregivers should regularly assess the cat's daily comfort and maintain open communication with the veterinarian. Pain, persistent nausea, refusal to eat, and social withdrawal are all warning signs of deteriorating quality of life.
10. References
- IRIS — International Renal Interest Society. IRIS Staging of CKD (modified 2023). iris-kidney.com
- Elliott J, et al. Survival of cats with naturally occurring chronic renal failure: effect of dietary management. JVIM. 2000;14(4):401-407.
- Ross SJ, et al. Clinical evaluation of dietary modification for treatment of spontaneous chronic kidney disease in cats. JAVMA. 2006;229(6):949-957.
- Hall JA, et al. Comparison of serum concentrations of symmetric dimethylarginine and creatinine as kidney function biomarkers in cats with chronic kidney disease. JVIM. 2014;28(6):1676-1683.
- Roudebush P, et al. An evidence-based review of therapies for canine and feline chronic kidney disease. JVIM. 2009;23(1):23-32.
- Sparkes AH, et al. ISFM Consensus Guidelines on the Diagnosis and Management of Feline CKD. JFMS. 2016;18(3):219-239.
- WSAVA Global Nutrition Committee. Nutritional Assessment Guidelines. 2024.